Journal Mobile Options
Table of Contents
Vol. 212, No. 1, 2006
Issue release date: November 2005
Dermatology 2006;212:31–35
(DOI:10.1159/000089019)

Bullous Erysipelas: Clinical Presentation, Staphylococcal Involvement and Methicillin Resistance

Krasagakis K. · Samonis G. · Maniatakis P. · Georgala S. · Tosca A.
Departments of aDermatology and bInternal Medicine, University Hospital of Heraklion, Heraklion, and cDepartment of Dermatology, A. Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Erysipelas is a bacterial infection of the dermis and hypodermis, mostly of streptococcal origin. Bullous erysipelas represents a severe form of the disease. Objective: To evaluate the clinical and microbiological characteristics and treatment of bullous erysipelas. Methods: Patients with a diagnosis of bullous erysipelas who were treated at the Department of Dermatology, University Hospital of Heraklion, Crete, Greece, between the years 1996 and 2001 were retrospectively studied. Results: Fourteen patients (11 women, 3 men) with bullous erysipelas were evaluated. The lesions were located on the legs and face in 9 and 4 patients, respectively. The median duration of disease before hospital admission was 4 days. Eight patients had fever at presentation. Local trauma and various lesions were common causes for pathogen entry. The initial empirical antibiotic treatment included intravenous β-lactams and was modified according to the sensitivities of the isolated strains. Staphylococcus aureus was isolated from 7 (50%), while S. warneri, Streptococcus pyogenes and Escherichia coli grew from the lesions of 3 other patients. Six out of 7 S. aureus strains were methicillin resistant (MRSA) but susceptible to several other non-β-lactam antibiotics such as quinolones, vancomycin, rifampicin and trimethoprim/sulfamethoxazole. Conclusion: Our findings suggest that S. aureus is frequently involved in and probably contributes in synergy with β-hemolytic streptococci to the complicated course of bullous erysipelas. The frequency of MRSA isolation suggests that β-lactam antibiotics may not be sufficient for the treatment of bullous erysipelas anymore, at least in areas with a high incidence of MRSA strains. The role of other classes of antibiotics providing adequate coverage for MRSA has to be evaluated in prospective clinical trials.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Binnick AN, Klein RB, Baughman RD: Recurrent erysipelas caused by group B streptococcus organisms. Arch Dermatol 1980;116:798–799.
  2. Bernard P, Bedane C, Mounier M, Denis F, Catanzano G, Bonnetblanc JM: Streptococcal cause of erysipelas and cellulitis in adults – A microbiologic study using a direct immunofluorescence technique. Arch Dermatol 1989;125:779–782.
  3. Chartier C, Grosshans E: Erysipelas. Int J Dermatol 1990;29:459–467.
  4. Eriksson B, Jorup-Ronstrom C, Karkkonen K, Sjoblom AC, Holm SE: Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis 1996;23:1091–1098.
  5. Eriksson BK: Anal colonization of group G β-hemolytic streptococci in relapsing erysipelas of the lower extremity. Clin Infect Dis 1999;29:1319–1320.
  6. Jorup-Ronstrom C: Epidemiological, bacteriological and complicating features of erysipelas. Scand J Infect Dis 1986;18:519–524.
  7. Guberman D, Gilead LT, Zlotogorski A, Schamroth J: Bullous erysipelas: a retrospective study of 26 patients. J Am Acad Dermatol 1999;41:733–737.
  8. Smolle J, Kahofer P, Pfaffentaler E, Kerl H: Risk factors for local complications in erysipelas. Hautarzt 2000;51:14–18.
  9. Dupuy A, Benchikhi H, Roujeau JC, Bernard P, Vaillant L, Chosidow O, Sassolas B, Guillaume JC, Grob JJ, Bastuji-Garin S: Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999;318:1591–1594.
  10. Roujeau J-C, Sigurgeirsson B, Korting H-C, Kerl H, Paul C: Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 2004;209:301–307.
  11. Mokni M, Dupuy A, Denguezli M, Dhaoui R, Bouassida S, Amri M, Fenniche S, Zeglaoui F, Doss N, Nouira R, Osman-Dhahri AB, Zili J, Kamoun MR, Zahaf A, Chosidow O: Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study. Dermatology, in press.
  12. Hugo-Persson M, Norlin K: Erysipelas and group G streptococci. Infection 1987;15:184–187.
  13. Dornbusch K, King A, Legakis N: Incidence of antibiotic resistance in blood and urine isolates from hospitalized patients – Report from a European collaborative study. European Study Group on Antibiotic Resistance (ESGAR). Scand J Infect Dis 1998;30:281–288.
  14. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D: Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003;22:406–419.
  15. Pantazatou A, Papaparaskevas J, Stefanou I, Papanicolas J, Demertzi E, Avlamis A: Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in a Greek tertiary care hospital, over an 8-year-period. Int J Antimicrob Agents 2003;21:542–546.
  16. Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus – An emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003;16:103–124.
  17. Naimi TS, LeDell KH: Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O’Boyle C, Danila RN, Lynfield R: Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976–2984.
  18. Cohen PR, Kurzrock R: Community-acquired methicillin-resistant Staphylococcusaureus infection: an emerging clinical problem. J Am Acad Dermatol 2004;50:277–280.
  19. Iyer S, Jones DH: Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004;50:854–858.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50